Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): NILK-2301

            Therapeutic Area: Oncology Product Name: NILK-2301

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: LamKap Bio Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 18, 2020

            Details:

            Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Derazantinib,Erdafitinib

            Therapeutic Area: Oncology Product Name: ARQ 087

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 28, 2020

            Details:

            The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors. Furthermore, derazantinib shows promising efficacy in patient-derived tumor models with gene aberrations in FGFR1-3.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T3P-Y058-739

            Therapeutic Area: Oncology Product Name: T3P-Y058-739

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: $27.4 million Upfront Cash: Undisclosed

            Deal Type: Financing July 22, 2020

            Details:

            T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.